Tariffs on generic drugs imported into the US will gradually increase from 0% to 200% over several years, encouraging companies to relocate production to the US.
The Office of the United States Trade Representative proposes additional tariffs of up to 12.5% on imports from 60 economies, citing unfair trade practices.
